RAPT Therapeutics (NASDAQ:RAPT) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of RAPT Therapeutics (NASDAQ:RAPT) from a sell rating to a hold rating in a research report released on Thursday.

RAPT has been the topic of several other reports. UBS Group decreased their price target on shares of RAPT Therapeutics from $2.00 to $1.00 and set a “neutral” rating on the stock in a research note on Thursday. HC Wainwright raised RAPT Therapeutics to a “strong-buy” rating and set a $6.00 price target for the company in a research report on Thursday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, RAPT Therapeutics presently has a consensus rating of “Hold” and an average target price of $3.00.

RAPT Therapeutics Stock Up 43.3%

Shares of NASDAQ RAPT opened at $1.23 on Thursday. The firm has a 50-day moving average price of $0.98 and a 200 day moving average price of $1.16. RAPT Therapeutics has a 52 week low of $0.71 and a 52 week high of $4.60. The stock has a market capitalization of $162.72 million, a price-to-earnings ratio of -0.44 and a beta of -0.04.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.23. Equities research analysts expect that RAPT Therapeutics will post -2.14 EPS for the current fiscal year.

Hedge Funds Weigh In On RAPT Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Simplicity Wealth LLC purchased a new stake in shares of RAPT Therapeutics during the first quarter worth about $25,000. Picton Mahoney Asset Management raised its position in shares of RAPT Therapeutics by 994.4% during the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock valued at $26,000 after acquiring an additional 14,697 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after buying an additional 25,130 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in RAPT Therapeutics in the fourth quarter worth about $63,000. Finally, Sei Investments Co. bought a new stake in shares of RAPT Therapeutics in the 4th quarter worth approximately $64,000. Hedge funds and other institutional investors own 99.09% of the company’s stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.